HopeStage
Back to all studies
CompletedNCT00095524

Weight change with aripiprazole or olanzapine in schizophrenia

About this titleRead the official source — NCT00095524
Medication studyAges 18–65Multiple countries
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
Little Rock and 31 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateMarch 2004
Recruitment status
Completed
Enrollment listed in the registry
300
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, United Kingdom, Brazil
Age range
From 18 Years to 65 Years
Official registry ID
NCT00095524
Official title
Show the full official title

A Multicenter, Randomized, Double-Blind Study on the Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Little Rock, United States · Anaheim, United States · Cerritos, United States

29 more locations
  • Garden Grove, United States
  • National City, United States
  • San Diego, United States
  • New Britain, United States
  • North Miami, United States
  • Augusta, United States
  • Macon, United States
  • Hoffman Estates, United States
  • Louisville, United States
  • Glen Burnie, United States
  • Haverhill, United States
  • Worcester, United States
  • Minneapolis, United States
  • Brooklyn, United States
  • Nashville, United States
  • Austin, United States
  • Dallas, United States
  • DeSoto, United States
  • San Antonio, United States
  • Wauwatosa, United States
  • Goibnia, Brazil
  • Belo Horizonte, Brazil
  • Rio de Janeiro, Brazil
  • Porto Alegre, Brazil
  • Botucatu, Brazil
  • Sao Paulo - Sp, Brazil
  • São Paulo, Brazil
  • Exeter, United Kingdom
  • Birmingham, United Kingdom

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Aripiprazole.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies